Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080429 | 1.00 | CYP3A4 (0.54) | CYP3A4SIRT2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8352429 | 0.84 | CYP3A4 (0.60) | CYP3A4SIRT2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5672405 | 0.84 | CA3 (0.40) | CYP3A4SIRT2DRD4CA3 | |
| SCHEMBL5672688 | 0.83 | DAO (0.41) | CYP3A4SLC6A3 | |
| SCHEMBL7085213 | 0.79 | TAAR1 (0.39) | CYP3A4 | |
| SCHEMBL5672795 | 0.79 | TAAR1 (0.39) | CYP3A4 | |
| SCHEMBL8980491 | 0.77 | LMNA (0.56) | — | |
| SCHEMBL7757693 | 0.76 | — | — | |
| SCHEMBL22530278 | 0.75 | GAA (0.48) | CYP3A4FASN | |
| SCHEMBL12371076 | 0.75 | CYP3A4 (0.51) | CYP3A4SIRT2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414463-A4 | ASYMMETRIC SYNTHESIS OF KAVALACTONES | SYNTA PHARMACEUTICALS CORP (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040204594-A1 | S-(+)-4-Methoxy-6-phenethyl-5,6-dihydro-pyran-2-one; plant extracts for nutraceutical foods, topical ointments | CHEN SHOUJUN (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1414463-A1 | ASYMMETRIC SYNTHESIS OF KAVALACTONES | Kava Pharmaceuticals, Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6677462-B2 | S-(+)-4-METHOXY-6-PHENETHYL-5,6-DIHYDRO-PYRAN-2-ONE; PLANT EXTRACTS FOR NUTRACEUTICAL FOODS, TOPICAL OINTMENTS | KAVA PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030236302-A1 | Synthetic derivatives | SYNTA PHARMACEUTICALS CORP. | 2003-12-25 | — | — | US | disclosed |
| WO-2003072103-A1 | SYNTHETIC DERIVATIVES | KAVA PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | SYNTA PHARMACEUTICALS CORP. | 2003-03-27 | — | — | US | disclosed |
| WO-2003013542-A1 | ASYMMETRIC SYNTHESIS OF KAVALACTONES | KAVA PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204594-A1 | S-(+)-4-Methoxy-6-phenethyl-5,6-dihydro-pyran-2-one; plant extracts for nutraceutical foods, topical ointments | KLF5, CYP8B1, CYP24A1 | CYP3A4 283/4885SIRT2 821/4885SLC6A2 3630/4885 |
| US-20030236302-A1 | Synthetic derivatives | CBR1, CBR3, REL | CYP3A4 169/4885SIRT2 1802/4885SLC6A2 4579/4885 |
| US-20030060633-A1 | Asymmetric synthesis of kavalactones | GNE, KLK14, ALG8 | CYP3A4 85/4885SIRT2 2394/4885SLC6A2 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.